Revolution Medicines' RASONQUE Nears EU Approval for Pancreatic Cancer After Strong Phase 3 Data
Event summary
- Revolution Medicines' RASONQUE (daraxonrasib) received a positive CHMP opinion for marketing authorization in the EU for metastatic pancreatic cancer.
- Phase 3 RASolute 302 trial showed a 60% reduction in risk of death compared to chemotherapy, with median overall survival of 13.2 months vs. 6.7 months.
- RASONQUE is the first broad RAS-targeted treatment option in the EU for metastatic pancreatic adenocarcinoma if approved by the European Commission.
- The positive CHMP opinion follows an expedited review under EMA’s Cancer Medicines Pathfinder project.
- RASONQUE was previously approved by the FDA on August 26, 2026.
The big picture
Revolution Medicines' RASONQUE represents a significant advancement in targeting RAS, a key driver of pancreatic cancer. The positive CHMP opinion underscores the growing recognition of innovative regulatory pathways, like the EMA’s Cancer Medicines Pathfinder project, in accelerating the approval of therapies for high unmet medical needs. The strategic focus on RAS-addicted cancers positions Revolution Medicines at the forefront of precision oncology, with potential implications for other aggressive malignancies.
What we're watching
- Regulatory Approval Timeline
- Whether the European Commission will swiftly approve RASONQUE, given the positive CHMP opinion and the drug's potential to address a high unmet medical need.
- Commercialization Strategy
- How Revolution Medicines plans to scale RASONQUE's availability across EU member states and other regions, following the potential EC approval.
- Clinical Pipeline Expansion
- The pace at which Revolution Medicines advances its global Phase 3 registrational program for RASONQUE in other indications, such as metastatic RAS mutant non-small cell lung cancer.
